Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Prostatic Neoplasms × efavirenz × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Triple Negative Breast Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Lymphoma, AIDS-Related 1 HIV Infections 1 Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Docetaxel 126 Prednisone 111 Abiraterone Acetate 83 Leuprolide 80 enzalutamide 76 Radiotherapy 54 Magnetic Resonance Spectroscopy 51 Goserelin 50 bicalutamide 47 Androgen Antagonists 47 apalutamide 42 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 41 abiraterone 31 Radiosurgery 31 cabazitaxel 28 Specimen Handling 28 Gonadotropin-Releasing Hormone 27 Carboplatin 26 gallium 68 PSMA-11 25 darolutamide 24 Estramustine 23 relugolix 21 luprolide acetate gel depot 21 Metformin 21 Triptorelin Pamoate 19 Radiation 18 Pluvicto 18 Brachytherapy 18 sipuleucel-T 17 radium Ra 223 dichloride 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00964002 2022-05-16

FAVE

Institut Bergonié

Phase 2 Completed

61 enrolled 6 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡